The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1308 articles
New research from the NIH reveals how semaglutide signaling in the brain affects weight loss plateaus, offering hope for improved efficacy and dosing strategies.
Discover how natural peptides are challenging the pharmaceutical industry, offering a new paradigm for healing, metabolic health, and cognitive enhancement amidst evolving regulatory landscapes.
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
Discover Retatrutide, a groundbreaking peptide with triple-receptor activity, poised to redefine metabolic health and weight management strategies. Learn about its science, potential, and what it means for the future of wellness.
Researchers at the University of Pennsylvania utilized artificial intelligence to analyze hundreds of thousands of Reddit posts, uncovering patient-reported side effects of GLP-1 medications that traditional clinical trials often overlook.
New data from D&D Pharmatech's Phase 2 trial for zabopegdutide, a GLP-1/glucagon dual receptor agonist, reveals promising results for patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This development positions zabopegdutide as a potential contender in a growing market.
Honey, once a simple pantry staple, is now sought after as a natural wellness tool. While it remains a form of sugar, emerging research suggests its unique composition—rich in antioxidants and oligosaccharides—offers distinct benefits over refined sweeteners, potentially aiding in weight control and gut health.
The landscape of weight loss treatments is rapidly changing with the introduction of oral GLP-1 medications. This article delves into early adoption trends, comparing the initial uptake of Eli Lilly's oral semaglutide (Foundao) against Novo Nordisk's oral semaglutide (Wegovy's pill), and what these patterns signify for patients and physicians.
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
